In Vivo Tests — Xenografts

Chapters in this book

1. Frontmatter 1
2. Contents 7
3. Introduction 11
4. Invasion and Metastasis as Targets for Tumour Therapy
5. Primary Invasion: Natural Inhibitors 15
6. Effect of Desacetyl Vinblastine Amide Sulphate or Vindesine (VDS) against the In Vivo Invasion and Formation of Tumour Metastasis 23
7. Invasion and Metastases as Targets for Tumour Therapy. An Overview 33
8. Invasiveness of Brain Tumour Cells In Vivo and In Vitro 42
9. Anti-inyasiveness of Microtubule Inhibitors is due to Interference with the Cytoplasmic Microtubule Complex 47
10. Metastasis: Mitostatic Drugs 55
11. Anticoagulant Treatment of Cancer 63
12. Reactivity of a Monoclonal Antibody (B72.3) with Fixed Sections of Human Mammary Carcinomas 66
13. Polyamine Oxidation in Relation to Tumour Growth and Metastasis 71
14. Partial Purification of an Epidermal Growth Inhibitor (Chalone) 83
15. Hormone. Receptors
16. Estradiol Receptor in Human Breast Cancers and Prognosis 87
17. External Quality Assessment Scheme of Estradiol Receptor Assay: An Italian Survey 93
18. Methodological and Clinical Studies of the Steroid Receptor Assay in Primary Breast Cancer 99
19. The Value of Hormone Receptor Assays for Prediction of the Effectiveness of Endocrine Therapy in Breast Cancer 104
20. The Cancer Cell Surface as a Target for Tumour Therapy
21. Normal and Pathological Cell Communication 113
22. The Cells Surface as Target for Alkylating Agents 119
23. The Synergistic Effect of Drugs and Antibodies 127
24. Cancerostatic Lectins 134
25. Ribosome-inactivating Proteina as Possible Chemotherapeutic Agents 142
26. Selective Targeting of Ricin A Chain to a Murine B Cell Tumour by Anti-Immunoglobulin Antibodies 147
27. Development of New Drugs
28. The Generation of Reactive Molecular Species during the Oxidation of 9-Hydroxyellipticine Derivatives. Interest of Prooxidant Compounds in the Design of Anti-Cancer Drugs. 159
29. Development of Nitroimidazoles 166
30. Development of New Drugs — Immunomodulating Agents 173
31. Development of Potential Clinical Alternatives to Hexamethylmelamine 180
32. Synergistic Interaction of an Alkylating Agent (Lycurim) and an Antimetabolite (Pyrazofurin) on Heptoma 3924A Cells in Culture 189
33. Phase II Evaluation of 4-Thiazolidine-Carboxylic Acid (Thioproline) in Advanced Epidermoid Head and Neck Tumours 194
34. The Effect of a Bifunctional N-Notrosoureido Derivative (GYKI-13324) on Experimental Metastasis Models 198
35. Long-term Toxic and Carcinogenic Effects of Cytostatic Drugs 201
36. VP 16-213 (Etoposide; NSC-141540; Vepesid): A Review 210
37. New Platinum Anti-Cancer Drugs 214
38. The Status of Proteolytic Enzymes in Oncology 225
39. Marcellomycin: A New Class II Anthracycline 231
40. Biological Response Modifiers
41. Interferon 239
42. Comparative Interferon-Inducing and Anti-Tumour Activity of Substituted Pyrimidinones 245
43. Influence of Human Leucocyte Interferon on Squamous-Cell Carcinoma of Uterine Cervix: Clinical, Histological and Histochemical Observations 253
44. Effect of Interferon on Malignant Head and Neck Tumours 256
45. Polyamines and Neoplasia: A Review of Present Knowledge of Their Function and Therapeutic Potential 258
46. Retinoids 269
47. The Role of Drug-Induced Differentiation in the Control of Tumour Growth 275
48. Modifying Effect of the Sex Hormonal Environment on the Growth of Basophilic Foci and Hepatocellular Carcinoma 282
49. Phase II Clinical Trial of cis-Dichlorodiammine Platinum (cis-DDP) in Metastatic Brain Tumours — a Preliminary Report 287
50. Adriamycin: Experimental Evidence of Carcinogenicity 292
51. Electroreduction, Mutagenicity and Antimicrobial Activity of 5-Nitroimidazole Derivatives 300
52. Mechanism of the Antileukemic Action of DTIC and its Benzenoid Analog DM-COOK in mice 309
53. Laboratory Assessment of Therapeutic Activity
54. The Role of In Vitro Techniques in Assessing Antineoplastic Therapeutic Activities 315
55. In Vivo Tests — Xenografts 327
56. Suitable Models for Long-Term Bioassays on the Therapeutic and Toxic effects of Antiblastic Drugs: Liver Angiosarcomas Produced in Sprague-Dawley Rats by Vinyl Chloride 339
57. Role of some Biological Parameters in Drug Sensitivity and Resistance of Tumour Cells 342
58. Analysis of Cytotoxic and Cytostatic Effects 349
59. An Appraisal of Current In Vivo and In Vitro Screening Methods 359
60. Clinical Relevance of some Useful Methods for In-Vitro Testing of Cytostatic Sensitivity in Cases of Ovarian Cancers 366
61. Immunoglobulin Producing Cell Infiltration in Colorectal Cancer Tissues Correlated with Patients Survival 369
62. Suitable Models for Long-Term Bioassays of Therapeutic and Toxic Effects of Antiblastic Drugs: Brain Tumours of Neuronal Cells and Primitive Bipotential Precursors Produced in Sprague-Dawley Rats by Vinyl Chloride 376
63. Laboratory Assessment of Therapeutic Activity (with Particular Regard to Chemotherapy): Relevant Animal Models 379
64. Biological Significance and Dose-Dependent Effect of 'Resistocell' on Peripheral Blood Leucocytes In Vitro 393
65. Human Serum Ribonuclease Activity as a Marker for Therapeutic Success in Ovarian Carcinoma 401
66. Biological Properties of the New Quinazoline Inhibitor of Thymidylate Synthetase CB 3717 404
67. Miscellaneous
68. Reactivation of Alkylation-Damaged Adenovirus 3 by Cell Cultures Derived from Human Tumours 413
69. Effects of Surgical and Radio-Chemotherapeutic Treatment on the Immunological Pattern in Malignant Glioma Patients 418
70. Control of Megacaryocyte Differentiation in Healthy and Leukemic Patients 423
71. Cytotoxic T Lymphocytes: Various Effects on Human Myeloma Cells 426
72. Analysis of AHH Inducibility Ratios and Distribution in Human Lymphocytes by TLC-Radioisotopic Assay 431
73. Antitumour Actitivy of New Nitrosoureas on Yoshida Sarcoma Ascites Cells In Vivo 438
74. The Mode of Action of Cyclophosphamide 445
75. Index 457
76. Appendix 465